Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 711 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopic Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

NCT06808477
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
BBT001, Placebo
Drug
Lead sponsor
Bambusa Therapeutics
Industry
Eligibility
18 Years to 72 Years
Enrollment
237 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Irvine, California • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 27, 2026, 5:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Stress-induced Scratching in Healthy and AD

NCT04174651
View directory record Official record
Conditions
Healthy, Atopic Dermatitis
Interventions
Trier Social Stress Test (TSST), Landscape Video
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 59 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 27, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis

NCT01469767
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Fluocinonide cream
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 27, 2026, 5:42 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel

NCT05253755
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DBI-001, Aqueous gel
Biological
Lead sponsor
DermBiont, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Austin, Texas • Mill Creek, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 27, 2026, 5:42 AM EDT
Not listed Phase 2 Interventional

Study in Subjects With Moderate Atopic Dermatitis

NCT03859986
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
ALX-101 Gel Vehicle, ALX-101 Gel 5%
Drug
Lead sponsor
Ralexar Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Aventura, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 27, 2026, 5:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Diluted Sodium Hypochlorite Solution and Moisturizers on Skin Barrier Function in Atopic Dermatitis

NCT02594969
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Bleach Bath and Moisturizers
Other
Lead sponsor
University of California, Davis
Other
Eligibility
8 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 27, 2026, 5:42 AM EDT
Recruiting Phase 3 Interventional

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

NCT06807281
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Abrocitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
11
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 27, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195

NCT02881853
View directory record Official record
Conditions
Healthy Volunteers, Atopic Disease
Interventions
XmAb7195, Placebo
Drug
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 27, 2026, 5:42 AM EDT
Active, not recruiting Phase 4 Interventional

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

NCT06572228
View directory record Official record
Conditions
Asthma
Interventions
dupilumab, Matching Placebo, ICS/LABA
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
51
States / cities
Bakersfield, California • La Jolla, California • Lancaster, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 27, 2026, 5:42 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

NCT05486208
View directory record Official record
Conditions
Healthy, Dermatitis, Atopic
Interventions
LY3844583, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 27, 2026, 5:42 AM EDT
Completed Phase 1 Interventional

Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

NCT06945458
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
KT-621
Drug
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
12
States / cities
Birmingham, Alabama • Fountain Valley, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 27, 2026, 5:42 AM EDT
Completed Phase 3 Interventional

To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)

NCT02601703
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tacrolimus Ointment 0.1%, Protopic® ointment, 0.1%, Placebo of Tacrolimus Ointment
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
60
States / cities
Tempe, Arizona • Anaheim, California • Bell Gardens, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 27, 2026, 5:42 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Probiotic Supplementation in Breastfed Newborn Infants

NCT02286999
View directory record Official record
Conditions
Atopic Dermatitis, Food Allergies
Interventions
B. infantis, Placebo
Drug
Lead sponsor
Emanual Maverakis, MD
Other
Eligibility
1 Day to 7 Days
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 27, 2026, 5:42 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Skin Barrier Abnormalities and Oxidative Stress Response

NCT04606615
View directory record Official record
Conditions
Atopic Dermatitis, Food Allergy
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
1 Year to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 27, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive

NCT05590338
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
GSK1070806, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Cypress, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 27, 2026, 5:42 AM EDT
Terminated Not applicable Interventional

Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients

NCT02713035
View directory record Official record
Conditions
Dermatitis, Atopic, Eczema
Interventions
Self help intervention
Behavioral
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
4 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 27, 2026, 5:42 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

NCT03654755
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ASN002
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
31
States / cities
Anniston, Alabama • Birmingham, Alabama • Fremont, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 27, 2026, 5:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Risk of Asthma in Infants With Atopic Dermatitis

NCT00459576
View directory record Official record
Conditions
Asthma, Eczema, Dermatitis, Atopic
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 7 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 27, 2026, 5:42 AM EDT
Recruiting Phase 4 Interventional

Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

NCT05042258
View directory record Official record
Conditions
Atopic Dermatitis, Sleep Disturbance
Interventions
Dupilumab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
6 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 27, 2026, 5:42 AM EDT
Recruiting No phase listed Observational

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

NCT05938478
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Tralokinumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2035
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 27, 2026, 5:42 AM EDT
Completed Phase 1 Interventional

Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07336940
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
ENV-294 Capsule
Drug
Lead sponsor
Enveda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Fremont, California • Louisville, Kentucky • College Station, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 27, 2026, 5:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03738397
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib, Dupilumab, Placebo to dupilumab, Placebo to upadacitinib
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 76 Years
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
52
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 27, 2026, 5:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT05601882
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 64 Years
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
58
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • North Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 27, 2026, 5:42 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients

NCT03948334
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ZPL389 30mg, ZPL389 50mg, TCS and/or TCI
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Litchfield Park, Arizona • Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 27, 2026, 5:42 AM EDT